Starpharma CEO to retire in 2024 (ASX Announcement)
Jun 9th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) wishes to advise that following her significant tenure as the Company’s Chief Executive Officer (CEO), Dr Jackie Fairley has advised the Board that she intends to retire during 2024. Jackie and the Board are keen to ensure an orderly transition and have agreed that she will continue in the role until a successor is ready to commence, providing leadership and continuity throughout the transition period.
Read More
VIRALEZE™ Nasal Spray Approved in Malaysia (ASX Announcement)
Jun 5th, 2023
Starpharma today announces that it has achieved regulatory approval for its antiviral nasal spray product, VIRALEZE™, in Malaysia. The registration will allow Starpharma and its commercial partners to market and sell the product in Malaysia, a country with a population of over 33 million.
Read More
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Apr 28th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 March 2023 (Q3 FY23). Starpharma’s net operating cash outflows for the quarter were $4.9 million, and the closing cash balance as at 31 March 2023 was $38.9 million.
Read More
HER2-targeted DEP® SN-38 ADC outperforms in HER2+ human cancer model (ASX Announcement)
Apr 26th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that it has developed a HER2-targeted DEP® SN-38 antibody-drug conjugate (ADC), which has shown significant anti-tumour activity in a HER2+ human ovarian cancer xenograft model, outperforming the approved ADC product, Enhertu®[1].
Read More
AZD0466 active in small cell lung cancer patient models (ASX Announcement)
Apr 20th, 2023
Starpharma (ASX: SPL, OTCQX: SPHRY) today announces AZD0466 results from a preclinical study in small cell lung cancer (SCLC) patient-derived xenograft (PDX) models. Starpharma’s partner, AstraZeneca, presented these results overnight at the American Association for Cancer Research (AACR) Annual Meeting.
Read More
DEP® cabazitaxel Phase 2 clinical trial completes enrolment and treatment (ASX Announcement)
Apr 17th, 2023
Starpharma today announces that it has completed enrolment and treatment of patients for the Phase 2 clinical trial of its investigational anticancer product DEP® cabazitaxel. Encouraging efficacy signals, including significant tumour shrinkage and substantial tumour biomarker reductions, have been observed in multiple cancer types, including prostate cancer, ovarian cancer, gastro-oesophageal cancer, cholangiocarcinoma and head and neck cancer, following treatment with DEP® cabazitaxel.
Read More.png)
Commencement of CFO and Company Secretary (ASX Announcement)
Apr 3rd, 2023
Melbourne, Australia; 3 April 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce that, further to the announcement on 3 March 2023, Mr Justin Cahill commences in the role of Chief Financial Officer (CFO) and Company Secretary today.
Read More
Starpharma presents at ASX Small and Mid-Cap Conference (ASX Announcement)
Mar 22nd, 2023
Melbourne, Australia; 22 March 2023: Starpharma (ASX: SPL, OTCQX: SPHRY) announces that Starpharma CEO Dr Jackie Fairley will present a brief overview of the Company at the ASX Small and Mid-Cap Conference today at 11:00am AEDT. The Conference showcases selected ASX-listed companies to Australian investors.
Read More
CFO and Company Secretary Appointment (ASX Announcement)
Mar 3rd, 2023
Melbourne, Australia; 3 March 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Mr Justin Cahill as Chief Financial Officer (CFO) and Company Secretary, following an extensive executive search process. Justin will commence in the role in early April 2023.
Read More
Interim Report and Half-Year Financial Results - H1FY23 (ASX Announcement)
Feb 28th, 2023
Melbourne, Australia; 28 February 2023: Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its interim report and half-year financial results for the period ended 31 December 2022 (H1 FY23).
Read More
Appointment of Company Secretary (ASX Announcement)
Feb 1st, 2023
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) advises, in accordance with ASX Listing Rule 3.16.1, that Ms Tracy Weimar from Vistra Australia has been appointed as interim Company Secretary, effective today.
Read More
Dr Russell Basser appointed as non-executive director (ASX Announcement)
Jan 31st, 2023
The Board of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Russell Basser as an independent non-executive director, effective from 20 February 2023.
Dr Basser is a medical oncologist and former corporate executive with over 30 years of international medical and biopharmaceutical experience, including 21 years at CSL.
Dr Basser has substantial expertise in international drug and vaccine development, having held multiple senior executive roles whilst at CSL, including Senior Vice President (SVP) of Research and Development at CSL Seqirus; Chief Medical Officer at CSL Limited / CSL Behring; and SVP of Global Clinical Research and Development at CSL Behring / CSL Limited.
Read More
Quarterly Activities Report & Appendix 4C (ASX Announcement)
Jan 30th, 2023
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today releases its Quarterly Activities Report and Appendix 4C for the period ended 31 December 2022 (Q2 FY23).
Starpharma’s cash balance as at 31 December 2022 was $44.0 million, with a positive net operating cash flow of $2.2 million for the quarter. Total receipts of $8.1 million in the quarter include $7.1 million received from the Australian Government under its R&D tax incentive scheme and receipts from customers of $1.0 million. Customer receipts, including from sales of VIRALEZE™ and VivaGel® BV, were up 59% from the previous quarter (Q1 FY23: $0.6 million).
Read More
Starpharma receives $7.1M R&D tax incentive refund (ASX announcement)
Dec 23rd, 2022
Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announces it has received a $7.1M research and development (R&D) tax incentive refund under the Australian Federal Government’s R&D Tax Incentive scheme.
Read More
Resignation of CFO / Company Secretary
Dec 21st, 2022
Starpharma today announces that after nearly 17 years with the Company, including 14 years as Chief Financial Officer (CFO), Mr Nigel Baade, has advised of his intention to leave Starpharma in early 2023 to pursue new professional opportunities.
Read More
Positive AZD0466 clinical data presented by AstraZeneca (ASX Announcement)
Dec 13th, 2022
Starpharma today announces preliminary AZD0466 clinical trial results from the ongoing Phase 1/2 trial in patients with advanced relapsed/refractory leukemia (NCT04865419), presented by Starpharma’s partner AstraZeneca at the 2022 American Society of Hematology (ASH) Annual Meeting today.
Read More
2022 Annual General Meeting - CEO's presentation
Dec 2nd, 2022
View/Download a copy of the CEO's presentation to shareholders at the 2022 Annual General Meeting, held on 29 November 2022.
Read More
Starpharma presents additional clinical data for DEP® cabazitaxel in prostate cancer (ASX Announcement)
Sep 12th, 2022
Starpharma announces additional results from the mCRPC cohort of its Phase 2 DEP® cabazitaxel trial, following completion of dosing in this cohort. Treatment with DEP® cabazitaxel showed a number of key advantages compared to published data for conventional cabazitaxel, including superior efficacy, as measured by longer PFS, and a lower incidence of key side effects, despite this patient cohort being relatively more heavily pre-treated.
Read More
Starpharma annual report and full year financial results
Aug 25th, 2022
Starpharma today released its annual report and financial results for the year ended 30 June 2022.
Read More
ADCs Built On Starpharma Delivery Tech To Be Tested By Merck
Aug 22nd, 2022
"As it works to expand its antibody-drug conjugate (ADC) capabilities, Merck has strengthened its links to Starpharma by signing a second partnership that will allow it to assess potential candidates using a dendrimer drug delivery technology", reports World Pharma Today.
Read More
Merck bags chance to test ADCs based on Starpharma delivery tech
Aug 16th, 2022
"Merck has tightened its ties to Starpharma as it continues to build out its antibody-drug conjugate (ADC) capabilities, signing a second agreement that will enable it to evaluate candidates based on a dendrimer drug delivery platform", as featured in Fierce Pharma.
Read More
Starpharma announces new research agreement for DEP drug delivery platform
Aug 11th, 2022
"Starpharma (ASX:SPL) has announced a new research agreement with MSD under which the Australian company will design and synthesise a number of DEP dendrimer conjugates and provide them to the US-based company for testing and characterisation," as reported in The National Tribune.
Read More
Starpharma (ASX:SPL) signs new DEP research agreement with MSD
Aug 10th, 2022
Following Starpharma's latest announcement, the company was featured in The Market Herald.
Read More
Starpharma signs new DEP® agreement with MSD (ASX Announcement)
Aug 10th, 2022
Starpharma today announced it has signed a new DEP® Research Agreement with MSD, the trade name of Merck Sharp & Dohme LLC, Rahway, NJ, USA. This new agreement follows an earlier DEP® Antibody Drug Conjugate (ADC) agreement signed with MSD in February 2021. Under the new agreement, Starpharma will design and synthesize a number of DEP® dendrimer conjugates and will provide them to MSD for testing and characterisation.
Read More
Starpharma one of a number of Australian companies in the US for major oncology conference
Jun 7th, 2022
"For the first time in more than two years, a number of Australian biotechnology companies are in the US for one of the world's most important oncology events - the global conference of the American Society of Clinical Oncology (ASCO)." Starpharma featured in Biotech Dispatch during its visit to the United States for ASCO.
Read More
Starpharma to present DEP® at Boston ADC summit (ASX Announcement)
Apr 27th, 2022
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that it will today present as an invited speaker at the Novel Format Conjugates Summit, an industry conference focusing on next generation Non-Traditional Antibody Drug Conjugates (ADCs) for oncology and beyond.
Read More
Dr Jeff Davies appointed as non-executive director (ASX Announcement)
Apr 1st, 2022
Melbourne, Australia; 1 April 2022: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced that Dr Jeff Davies has commenced as an independent non-executive director, effective 1 April 2022. ... Dr Davies is a former CSL executive, with over 35 years of biopharmaceutical experience, holding senior executive roles at CSL, including Executive Vice President & General Manager at... Read More
Dr Jeff Davies appointed as non-executive director (ASX Announcement)
Feb 24th, 2022
Starpharma Holdings Limited The Board of Starpharma (ASX: SPL, OTCQX: SPHRY) is pleased to announce the appointment of Dr Jeff Davies as an independent non-executive director, effective 1 April 2022.
Read More
Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer
Nov 30th, 2021
Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.
Read More
Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer
Nov 27th, 2021
Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha.
Read More
Starpharma Releases Positive DEP® Phase 2 Interim Results In Prostate Cancer
Nov 27th, 2021
British Herald reports on Starpharma's announcement, regarding the positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP® cabazitaxel.
Read More
Starpharma Announces Encouraging Interim Results for Prostate Cancer Drug
Nov 27th, 2021
Gene Online reports on the news of Starpharma's latest announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.
Read More
Positive DEP® phase 2 interim results in prostate cancer (ASX Announcement)
Nov 25th, 2021
Starpharma today announced positive interim results from its ongoing phase 2 trial of DEP® cabazitaxel, showing that 100% (22/22) of evaluable patients with hormone refractory, (Stage IV) metastatic prostate cancer. All of these patients have been heavily pre-treated and have had efficacy responses, utilising one or more standard measures of disease.
Read More
AstraZeneca to present AZD0466 posters at ASH Meeting
Nov 5th, 2021
AstraZeneca will present two scientific posters each accompanied by a presentation at the 2021 American Society of Hematology (ASH) Annual Meeting, showcasing AstraZeneca’s first DEP® oncology product, AZD0466.
Read More
Starpharma to present DEP® at US Drug Delivery Conference (ASX Announcement)
Oct 28th, 2021
Starpharma today announced that it has been invited to present at the 11th annual Partnership Opportunities in Drug Delivery (PODD) conference, which will take place virtually this year on 28‑29 October 2021.
Read More
2021 Annual General Meeting (ASX Announcement)
Oct 1st, 2021
Starpharma today notifies that the AGM of Starpharma Holdings Limited will be held as a virtual event at 11:00am (Melbourne time) on Tuesday, 30 November 2021.
Read More
US patent issued for DEP® cabazitaxel nanoparticle (ASX Announcement)
Sep 15th, 2021
Starpharma today announced that the US Patent and Trademark Office has granted a new patent in relation to DEP® cabazitaxel.
Read More